Evidence map›Paper›PMID 29789335›Full record

Observational studyJournal of the American Heart Association2018

Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores.

Masahiro Natsuaki, Takeshi Morimoto, Kyohei Yamaji, Hirotoshi Watanabe, Yusuke Yoshikawa, Hiroki Shiomi, Yoshihisa Nakagawa, Yutaka Furukawa, Kazushige Kadota, Kenji Ando and 8 more

Open access · goldAbstract readObservational StudyValidation Study
In one paragraph

Observational study in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 192 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Trial
  8. Article
  9. Observational
  10. Observational
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Prognostic value of HELT-ECardiovascular intervention and therapeutics · 2025
    Observational
  19. Article
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

Masahiro NatsuakiDepartment of Cardiovascular Medicine, Saga University, Saga, Japan.
Takeshi MorimotoDepartment of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
Kyohei YamajiDivision of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
Hirotoshi WatanabeDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yusuke YoshikawaDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroki ShiomiDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yoshihisa NakagawaDivision of Cardiology, Tenri Hospital, Tenri, Japan.
Yutaka FurukawaDepartment of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Kazushige KadotaDivision of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
Kenji AndoDivision of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
Takashi AkasakaDepartment of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan.
Keiichi Igarashi HanaokaDivision of Cardiology, Hanaokaseishu Memorial Cardiovascular Clinic, Sapporo, Japan.
Ken KozumaDivision of Cardiology, Teikyo University Hospital, Tokyo, Japan.
Kengo TanabeDivision of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Yoshihiro MorinoDivision of Cardiology, Iwate Medical University Hospital, Morioka, Japan.
Toshiya MuramatsuDivision of Cardiology, Tokyo Hospital, Tokyo, Japan.
Takeshi KimuraDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan taketaka@kuhp.kyoto-u.ac.jp.
CREDO‐Kyoto PCI/CABG Registry Cohort 2, RESET, and NEXT trial investigators
Kyoto University · JPKokura Memorial Hospital · JPHyogo Medical University · JPIwate Medical University · JPKobe City Medical Center General Hospital · JPKurashiki Central Hospital · JPMitsui Memorial Hospital · JPSaga University · JPTeikyo University Hospital · JPTenri Hospital · JPWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrediction of thrombotic and bleeding risk is important to optimize antithrombotic therapy after percutaneous coronary intervention. METHODS AND

resultsWe developed the prediction rules for thrombotic and bleeding events separately in Japanese patients. Derivation and validation cohorts consisted of 4778 patients from CREDO-Kyoto (Coronary Revascularization Demonstrating Outcome Study in Kyoto) registry cohort 2 and 4669 patients from RESET (Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial) and NEXT (Nobori Biolimus-Eluting Versus Xience/Promus Everolimus-Eluting Stent Trial). Primary thrombotic and bleeding events were a composite of myocardial infarction, definite or probable stent thrombosis or ischemic stroke, and GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) moderate or severe bleeding. The prediction rule for thrombosis assigned 2 points for severe chronic kidney disease, atrial fibrillation, peripheral vascular disease, and anemia and 1 point for age ≥75 years, heart failure, diabetes mellitus, and chronic total occlusion. The prediction rule for bleeding assigned 2 points for thrombocytopenia, severe chronic kidney disease, peripheral vascular disease, and heart failure and 1 point for prior myocardial infarction, malignancy, and atrial fibrillation. In derivation and validation cohorts, area under the curve was 0.68 and 0.64, respectively, for thrombosis and 0.66 and 0.66, respectively, for bleeding. In the validation cohort, a high thrombosis risk score (≥4, n=682) was associated with higher 3-year incidence of thrombotic events than a score that was intermediate (2-3, n=1178) or low (0-1, n=2809) (7.6%, 3.7%, versus 2.4%, respectively;

conclusionsCREDO-Kyoto thrombotic and bleeding risk scores demonstrated modest accuracy in stratifying thrombotic and bleeding risks; however, a large proportion of patients at high thrombotic risk also had high bleeding risk.

Indexed as

Decision Support TechniquesAgedCoronary ThrombosisDatabases, FactualFemaleFibrinolytic AgentsHemorrhageHumansJapanMaleMiddle AgedPercutaneous Coronary InterventionPredictive Value of TestsRandomized Controlled Trials as TopicRegistriesReproducibility of ResultsFibrinolytic Agentsbleedingcoronary artery diseasethrombosis

Identifiers

PMID29789335
PMCPMC6015347
OpenAlexW2804251795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.